Magrolimab
- Generic Name
- Magrolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169232-81-7
- Unique Ingredient Identifier
- 90YIEHRFJ9
- Background
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 378
- Registration Number
- NCT05079230
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UC Irvine Health- Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸The University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT04958785
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇺🇸Charleston Oncology, Charleston, South Carolina, United States
🇦🇺Peninsula Health, Frankston, Victoria, Australia
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 193
- Registration Number
- NCT04854499
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
🇧🇪Algemeen Ziekenhuis Klina, Brasschaat, Belgium
Study of Magrolimab in Patients With Solid Tumors
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 106
- Registration Number
- NCT04827576
- Locations
- 🇺🇸
Tallahassee Memorial Healthcare Cancer Center, Tallahassee, Florida, United States
🇺🇸University of Miami, Deerfield Beach, Florida, United States
🇺🇸Virginia Piper Cancer Center (Alliant Health), Saint Paul, Minnesota, United States
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 8
- Registration Number
- NCT04788043
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University, Stanford, California, United States
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 258
- Registration Number
- NCT04778397
- Locations
- 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Magrolimab Combinations in Participants With Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT04778410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT04751383
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04599634
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.